Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in Refractory/Recurrent Acute Myeloid Leukemia: a Single-arm, Non-blind Clinical Study

NCT05943314 is registered in ClinicalTrials.gov with Guangzhou Bio-gene Technology Co., Ltd as lead sponsor.

NCT NCT05943314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05943314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in Refractory/Recurrent Acute Myeloid Leukemia: a Single-arm, Non-blind Clinical Study
Lead sponsor
Guangzhou Bio-gene Technology Co., Ltd
Phase
Not applicable
Overall status
Withdrawn
Start date
July 12, 2023
Completion date
August 28, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia